Summary
Ten patients with previously untreated stage III/IV low grade histology non-Hodgkin's lymphoma received a 1-hour intravenous infusion of Didemnin B 2.3 mg/m2 weekly for 4 weeks repeated every 6 weeks. 40% of patients experienced significant hypersensitivity reactions, one of which was life-threatening, despite premedication with diphenhydramine and cimetidine. Other toxicities included nausea, vomiting, fatigue, diarrhea and skin rashes. No objective responses were seen. Given the serious toxicity and lack of activity in a non-pretreated group of patients, the study was closed early. Further investigation of Didemnin B at this dose and schedule is not recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ca-A Cancer Journal for Clinicians. Cancer Statistics 1991. American Cancer Society Jan/Feb 41(1):28, 1991
Eyne HJ, Farver ML: Hodgkin's disease and non-Hodgkin's lymphoma. In: Holleb AI, Fink DJ, Murphy GP (eds) American Cancer Society Textbook of Clinical Oncology. The American Cancer Society Inc., Atlanta, 1991, pp 385–396
Matia LA, Young RC, Longo DL: Nodular lymphomas: Current concepts. Crit Rev Oncol Hematol 5:171–197, 1986
Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr: The treatment of indolent lymphomas: Watchful waiting vs aggressive modality treatment. Semin Hematol 25 (Suppl 2):11–16, 1988
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE: Hydroxyldaunomycin therapy (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484–1493, 1976
Jones SE, Grozea PN, Miller TP, Van Slyck EJ, Balcerzak SP, Costanzi JJ, Morrison FS, Eyre HJ, Fabian CJ, Dabich L: Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone alone or with levamisole plus BCG for malignant lymphoma. A Southwest Oncology Group study. J Clin Oncol 3:1318–1324, 1985
Longo DL, Young RC, Hubbard SM, Wesley M, Fisher RI, Jaffe E, Berard C, De Vita VT Jr: Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 100:651–656, 1984
Glick JH, Barnes JM, Ezdinli EZ, Berard CW, Orlow EL, Bennett JM: Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged diseasefree survival with COPP chemotherapy. Blood 58:920–925, 1981
Rhinehart KL Jr, Gloer JB, Hughes RG Jr, Renis HE, McGovern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li HL: Didemnins: antiviral and antitumour depsipeptides from a Caribbean tunicate. Science 212:933–935, 1981
Weed S, Stringfellow DA: Didemnins A and B: Effectiveness against cutaneous herpes simplex viruses in mice. Antiviral Res 3:269–274, 1983
Rhinehart KL Jr, Gloer JB, Cook JC Jr, Mizsak SA, Scahill TA: Structures of the Didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 103:1857–1859, 1981
Portlock CS, Fischer DS, Cadman E, Lundberg WB, Levy WB, Levy A, Bobrow S, Betino JR, Farber L: High dose pulse chlorambucil in advanced low-grade non-Hodgkin's lymphoma. Cancer Treat Rep 71:1029–1031, 1987
Portlock CS, Rosenberg SA, Glatstein E, Kaplan HS: Treatment of advanced non-Hodgkin's lymphomas with favourable histologies. Preliminary results of a prospective trial. 47:747–756, 1976
Hoppe RT, Kushian P, Kaplan HS, Rosenberg SA, Brown BW: The treatment of advanced stage favourable non-Hodgkin's lymphoma a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 58:592–598, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goss, G., Muldal, A., Lohmann, R. et al. Didemnin B in favourable histology non-Hodgkin's lymphoma. Invest New Drugs 13, 257–260 (1995). https://doi.org/10.1007/BF00873810
Issue Date:
DOI: https://doi.org/10.1007/BF00873810